Sac Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -86.02%
- Profit Growth -498.94%
- Ebitda -195.53%
- Net Worth -31.55%
- Total Assets -32.18%
About Sac Pharma
Sac Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 August 2011 and has a history of 13 years and six months. Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Irfan Ali, Faisal Irfan, and Saudagar Maseeha serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909DL2011PTC223914
- Company No.
223914
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Aug 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Sac Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Irfan Ali  | Managing Director | 19-Aug-2011 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Faisal Irfan | Additional Director | 17-May-2022 | Current |
| Saudagar Maseeha | Director | 20-Mar-2024 | Current |
Financial Performance of Sac Pharma.
Sac Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 86.02% decrease. The company also saw a substantial fall in profitability, with a 498.94% decrease in profit. The company's net worth observed a substantial decline by a decrease of 31.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sac Pharma?
Unlock access to Sac Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sac Pharma?
Unlock and access historical data on people associated with Sac Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sac Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sac Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
